NLRP3 and autoimmune disease: Importantly, we indeed observed that dysregulation of these autocrine pathways affects the inflammatory responses in autoimmune disease: CD4+ T cells from patients with CAPS, who express mutated, constitutively‐active NLRP3, and have increased autocrine IL‐1β secretion exhibit strongly increased Th1 responses that are normalized by treatment with the NLRP3 inflammasome‐specific inhibitor MCC950 58, 90.